ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  IDrugs : the investigational drugs journal

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 18988128
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the ability of recombinant human parathyroid hormone, rhPTH-(1–84), and hPTH-(1–31)NH2 to stimulate femoral trabecular bone growth in ovariectomized rats

  2009cited by this paper
• Adynamic bone in patients with chronic kidney disease.

  2008cited by this paper
• Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats.

  2008cited by this paper
• On the Interpretation of Rat Carcinogenicity Studies for Human PTH(1‐34) and Human PTH(1‐84)

  2008cited by this paper
• Building bone to reverse osteoporosis and repair fractures.

  2008cited by this paper
• Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis

  2008cited by this paper
• Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor.

  2008cited by this paper
• The use of parathyroid hormone in the treatment of osteoporosis

  2007cited by this paper
• Variations in animal populations over time and differences in diagnostic thresholds used can impact tumor incidence data.

  2007cited by this paper
• Effects of Treatment of Ovariectomized Adult Rhesus Monkeys with Parathyroid Hormone 1-84 for 16 Months on Trabecular and Cortical Bone Structure and Biomechanical Properties of the Proximal Femur

  2007cited by this paper
• Mechanisms of anabolic therapies for osteoporosis.

  2007cited by this paper
• Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis

  2007cited by this paper
• Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys.

  2007cited by this paper
• Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025

  2007cited by this paper
• Daily Treatment of Aged Ovariectomized Rats with Human Parathyroid Hormone (1-84) for 12 Months Reverses Bone Loss and Enhances Trabecular and Cortical Bone Strength

  2006cited by this paper
• Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.

  2006cited by this paper
• Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid Hormone 1–84 in a 2-Year Study in Fischer 344 Rats

  2006cited by this paper
• Parathyroid hormone activates PKC-delta and regulates osteoblastic differentiation via a PLC-independent pathway.

  2006cited by this paper
• Update of current therapeutic options for the treatment of postmenopausal osteoporosis.

  2006cited by this paper
• Treatment of Skeletally Mature Ovariectomized Rhesus Monkeys With PTH(1‐84) for 16 Months Increases Bone Formation and Density and Improves Trabecular Architecture and Biomechanical Properties at the Lumbar Spine

  2006cited by this paper
• Who are candidates for prevention and treatment for osteoporosis?

  2005cited by this paper
• Teriparatide [Human PTH(1‐34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis

  2005cited by this paper
• Continuous PTH and PTHrP Infusion Causes Suppression of Bone Formation and Discordant Effects on 1,25(OH)2Vitamin D

  2005cited by this paper
• Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6‐Month Double‐Blind Placebo‐Controlled Trial

  2005cited by this paper
• Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands.

  2005cited by this paper
• Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice.

  2005cited by this paper
• Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

  2005cited by this paper
• Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.

  2005cited by this paper
• Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters

  2005cited by this paper
• Parathyroid hormone and parathyroid hormone-related peptide, and their receptors.

  2005cited by this paper
• Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34).

  2005cited by this paper
• Modified bacterial mutation test procedures for evaluation of peptides and amino acid-containing material.

  2005cited by this paper
• Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis

  2005cited by this paper
• New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism

  2005cited by this paper
• Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose

  2004cited by this paper
• Teriparatide [PTH(1–34)] Strengthens the Proximal Femur of Ovariectomized Nonhuman Primates Despite Increasing Porosity

  2004cited by this paper
• Treatment with Parathyroid Hormone hPTH(1-34), hPTH(1-31), and Monocyclic hPTH(1-31) Enhances Fracture Strength and Callus Amount After Withdrawal Fracture Strength and Callus Mechanical Quality Continue to Increase

  2004cited by this paper
• The effects of parathyroid hormone fragments on bone formation and their lack of effects on the initiation of colon carcinogenesis in rats as indicated by preneoplastic aberrant crypt formation.

  2003cited by this paper
• Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure.

  2003cited by this paper
• The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.

  2003cited by this paper
• Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.

  2003cited by this paper
• Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.

  2003cited by this paper
• The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

  2003cited by this paper
• Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety

  2002cited by this paper
• Developments in parathyroid hormone and related peptides as bone-formation agents.

  2002cited by this paper
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

  2001cited by this paper
• Intermittently Administered Human Parathyroid Hormone(1–34) Treatment Increases Intracortical Bone Turnover and Porosity Without Reducing Bone Strength in the Humerus of Ovariectomized Cynomolgus Monkeys

  2001cited by this paper
• Stimulation of Protein Kinase C Activity in Cells Expressing Human Parathyroid Hormone Receptors by C‐ and N‐Terminally Truncated Fragments of Parathyroid Hormone 1–34

  2001cited by this paper
• The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1-31)NH2 on bone formation and mechanical strength in ovariectomized rats

  2001cited by this paper
• The Stimulation of Vertebral and Tibial Bone Growth by the Parathyroid Hormone Fragments, hPTH-(1-31)NH2, [Leu27]cyclo(Glu22-Lys26)hPTH-(1-31)NH2, and hPTH-(1-30)NH2

  2000cited by this paper
• Stimulation of membrane-associated protein kinase-C activity in spleen lymphocytes by hPTH-(1-31)NH2, its lactam derivative, [Leu27]-cyclo(Glu22-Lys26)-hPTH-(1-31)NH2, and hPTH-(1-30)NH2.

  1999cited by this paper
• Prolonged low-dose infusion of human parathyroid hormone does not increase femoral cancellous bone volume in ovariectomized rats.

  1999cited by this paper
• Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys.

  1999cited by this paper
• Cell-specific signaling and structure-activity relations of parathyroid hormone analogs in mouse kidney cells.

  1999cited by this paper
• Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.

  1998cited by this paper
• Comparison of the Abilities of Human Parathyroid Hormone (hPTH)-(1-34) and [Leu27]-cyclo(Glu22-Lys26)-hPTH-(1-31)NH2 to Stimulate Femoral Trabecular Bone Growth in Ovariectomized Rats

  1998cited by this paper
• Type-1 parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptors activate phospholipase C in response to carboxyl-truncated analogs of PTH(1-34).

  1998cited by this paper
• Structure based design of parathyroid hormone analogs.

  1997cited by this paper
• Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: cyclic lactams of the receptor binding region.

  1997cited by this paper
• Cyclization by a Specific Lactam Increases the Ability of Human Parathyroid Hormone (hPTH)‐(1–31)NH2 to Stimulate Bone Growth in Ovariectomized Rats

  1997cited by this paper
• Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans.

  1997cited by this paper
• Stimulation of the growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment, hPTH-(1–31)NH2 (Ostabolin)

  1996cited by this paper
• Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis.

  1995cited by this paper
• Further definition of the protein kinase C activation domain of the parathyroid hormone

  1994cited by this paper
• Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase

  1994cited by this paper
• Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients.

  1993cited by this paper
• The protein kinase-C activation domain of the parathyroid hormone.

  1992cited by this paper

• Emerging therapies for osteoporosis.

  2014cites this paper
• Emerging therapies for the treatment of osteoporosis

  2013cites this paper
• New Approaches to Osteoporosis Therapeutics

  2013cites this paper
• Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis

  2011influential citation
• Current and emerging therapies for the treatment of osteoporosis

  2010cites this paper
• Investigational anabolic therapies for osteoporosis

  2010cites this paper